Search for 'Provider:Annals of oncology: official journal of the European Society for Medical Oncology / ESMO, and itype:ART'

Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials.

By Paz-Ares Rodríguez, Luis. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, 2016 . 27(3):423-9. , Formato Vancouver: Ramalingam SS, O'Byrne K, Boyer M, Mok T, Jänne PA, Zhang H et al. Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials. Ann Oncol. 2016 Mar;27(3):423-9.

Place Hold on Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials.

Correlation of EGFR-expression with safety and efficacy outcomes in SQUIRE: a randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin plus necitumumab versus gemcitabine-cisplatin alone in the first-line treatment of patients with stage IV squamous non-small-cell lung cancer.

By Paz-Ares Rodríguez, Luis. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, 2016 . 27(8):1573-9. , Formato Vancouver: Paz-Ares L, Socinski MA, Shahidi J, Hozak RR, Soldatenkova V, Kurek R et al. Correlation of EGFR-expression with safety and efficacy outcomes in SQUIRE: a randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin plus necitumumab versus gemcitabine-cisplatin alone in the first-line treatment of patients with stage IV squamous non-small-cell lung cancer. Ann Oncol. 2016 Aug;27(8):1573-9.

Place Hold on Correlation of EGFR-expression with safety and efficacy outcomes in SQUIRE: a randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin plus necitumumab versus gemcitabine-cisplatin alone in the first-line treatment of patients with stage IV squamous non-small-cell lung cancer.

Role of circulating tumor cells as prognostic marker in resected stage III colorectal cancer.

By Grávalos Castro, Cristina. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, 2015 . ;26(3):535-41. , Formato Vancouver: Sotelo MJ, Sastre J, Maestro ML, Veganzones S, Viéitez JM, Alonso V et al. Role of circulating tumor cells as prognostic marker in resected stage III colorectal cancer. Ann Oncol. 2015 Mar;26(3):535-41.

Place Hold on Role of circulating tumor cells as prognostic marker in resected stage III colorectal cancer.

Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE).

By Castellano, Daniel. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, 2015 . 26(9):1987-93. , Formato Vancouver: Grande E, Capdevila J, Castellano D, Teulé A, Durán I, Fuster J et al. Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE). Ann Oncol. 2015 Sep; 26(9):1987-93.

Place Hold on Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE).

A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer.

By Brandariz Castelo, José Antonio | Hitt Sabag, Ricardo. Annals of oncology: official journal of the European Society for Medical Oncology / ESMO, 2014 . 25(1):216–225. , Formato Vancouver: Hitt R, Grau JJ, López-Pousa A, Berrocal A, García-Girón C, Irigoyen A et al. Spanish Head and Neck Cancer Cooperative Group (TTCC). A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer. Ann Oncol. 2014 Jan;25(1):216-25.

Place Hold on A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer.